TG Therapeutics Inc. (TGTX) Receives Average Recommendation of “Buy” from Analysts
Shares of TG Therapeutics Inc. (NASDAQ:TGTX) have received an average rating of “Buy” from the eight analysts that are currently covering the company. One research analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $21.90.
TGTX has been the topic of several research analyst reports. Roth Capital restated a “buy” rating and set a $33.00 price target on shares of TG Therapeutics in a report on Wednesday, August 10th. Brean Capital restated a “buy” rating and set a $28.00 price target on shares of TG Therapeutics in a report on Thursday, October 6th. FBR & Co restated a “buy” rating on shares of TG Therapeutics in a report on Monday, September 19th. S&P Equity Research lowered their price target on shares of TG Therapeutics from $7.15 to $6.40 in a report on Wednesday, August 24th. Finally, HC Wainwright restated a “buy” rating and set a $18.00 price target (down from $22.00) on shares of TG Therapeutics in a report on Saturday.
Large investors have recently added to or reduced their stakes in the stock. A.R.T. Advisors LLC acquired a new stake in TG Therapeutics during the second quarter valued at about $537,000. Guggenheim Capital LLC raised its stake in TG Therapeutics by 36.8% in the second quarter. Guggenheim Capital LLC now owns 164,213 shares of the biopharmaceutical company’s stock valued at $995,000 after buying an additional 44,192 shares during the last quarter. Citadel Advisors LLC acquired a new stake in TG Therapeutics during the second quarter valued at about $267,000. KCG Holdings Inc. acquired a new stake in TG Therapeutics during the second quarter valued at about $263,000. Finally, Mariner Wealth Advisors LLC raised its stake in TG Therapeutics by 4.4% in the second quarter. Mariner Wealth Advisors LLC now owns 19,086 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 800 shares during the last quarter. 54.66% of the stock is owned by institutional investors and hedge funds.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/17/tg-therapeutics-inc-tgtx-receives-average-recommendation-of-buy-from-analysts.html
Shares of TG Therapeutics (NASDAQ:TGTX) traded down 6.68% during mid-day trading on Monday, hitting $6.15. The stock had a trading volume of 382,859 shares. The stock has a 50-day moving average price of $7.39 and a 200 day moving average price of $7.37. TG Therapeutics has a 52 week low of $5.41 and a 52 week high of $14.87. The stock’s market cap is $334.90 million.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.29) by $0.04. TG Therapeutics had a negative net margin of 40,142.11% and a negative return on equity of 58.77%. On average, equities analysts forecast that TG Therapeutics will post ($1.22) EPS for the current fiscal year.
TG Therapeutics Company Profile
TG Therapeutics, Inc (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for b-cell malignancies and autoimmune diseases. The Company is developing over two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the CD20 antigen found on mature B-lymphocytes.
Receive News & Ratings for TG Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.